T
22 November 2026 · 4 views

ACS Prostate Cancer Screening: Biennial PSA Testing

ACS Prostate Cancer Screening: What Biennial PSA Testing Means

The American Cancer Society (ACS) does not recommend one prostate cancer screening schedule for every man. Instead, it supports an informed discussion between a man and a healthcare professional before prostate-specific antigen (PSA) testing begins.

For men who choose screening, the interval may depend partly on the PSA result. Men with a PSA level below 2.5 nanograms per milliliter (ng/mL) may be able to repeat testing every two years, while men with higher levels may need annual testing. Source 1

“Biennial” means once every two years. It does not mean that every average-risk man should automatically receive a PSA test every two years, regardless of age, health, family history, previous results, or personal preferences.

PSA testing measures a protein produced by prostate tissue. The test can help estimate the likelihood of prostate cancer, but it cannot diagnose cancer on its own. An abnormal result may lead to repeat testing, additional biomarkers, imaging, or biopsy.

The American Cancer Society’s Screening Approach

Screening begins with shared decision-making

The ACS recommends discussing the potential benefits, limitations, and uncertainties of PSA screening with a healthcare professional before testing. The discussion should cover:

  • The possibility of detecting aggressive cancer earlier.
  • False-positive and false-negative results.
  • The potential need for repeat testing, imaging, or biopsy.
  • The risk of detecting slow-growing cancer that might never cause symptoms.
  • Possible treatment effects, including urinary, bowel, and sexual problems.
  • Age, overall health, life expectancy, family history, and personal preferences.

A screening guideline provides a framework. It does not replace an individualized medical decision.

What biennial PSA testing means

Biennial screening means testing once every two years. It differs from annual testing, one-time testing, diagnostic testing prompted by symptoms, and risk-based testing adjusted for factors such as family history or previous results.

Under the ACS approach, men with PSA levels below 2.5 ng/mL may be able to repeat testing every two years. Men with levels of 2.5 ng/mL or higher may need yearly testing. The schedule can change after an abnormal result, a rapidly changing PSA level, suspicious imaging, or a clinician’s risk assessment. Source 1

The two-year interval is therefore not a universal rule for all average-risk men. It is one part of a broader screening strategy.

Screening ages depend on risk

The ACS recommends discussing screening at different ages according to risk:

  • Age 50: Men at average risk who are expected to live at least 10 more years.
  • Age 45: Men at high risk, including Black men and men with a first-degree relative, such as a father or brother, diagnosed with prostate cancer before age 65.
  • Age 40: Men at even higher risk, including those with more than one first-degree relative diagnosed with prostate cancer at an early age.

These ages indicate when to begin a screening discussion, not when every man must be tested. A healthcare professional should confirm which category applies. Source 1

Who Is an Average-Risk Man?

“Average risk” generally describes a man without recognized factors that substantially increase the likelihood of prostate cancer. Definitions can vary between organizations and clinical settings.

An average-risk man may have:

  • No strong family history of prostate cancer.
  • No known inherited variant linked to increased prostate cancer risk.
  • No previous abnormal PSA result requiring special monitoring.
  • No suspicious prostate imaging or biopsy.
  • No diagnosis requiring specialized cancer surveillance.

Average risk does not mean zero risk. Prostate cancer can occur without a known family history or genetic risk factor.

Factors associated with higher risk

A man may need an earlier or more individualized discussion if he has:

  • A father, brother, or son with prostate cancer.
  • Several relatives with prostate, breast, ovarian, pancreatic, or related cancers.
  • A family history of early-onset, aggressive, or metastatic prostate cancer.
  • A known inherited cancer-risk variant, including certain BRCA gene variants.
  • Black or African American identity, which the ACS recognizes as a higher-risk category for screening discussions.

Risk can also depend on the number of affected relatives, their ages at diagnosis, and whether cancers occurred on the same side of the family. Men should record cancer diagnoses among parents, siblings, children, grandparents, aunts, and uncles when possible. This information can help determine whether genetic counseling or earlier screening is appropriate. Source 2

How the PSA Test Works

PSA is a protein produced mainly by prostate tissue. A blood test measures its concentration in the bloodstream.

A higher PSA level can be associated with prostate cancer, but it can also result from noncancerous conditions. No single PSA value proves or excludes cancer in every man.

Clinicians interpret PSA in context, considering:

  • Age and prostate size.
  • Previous PSA results.
  • Family history, race, and inherited risk.
  • Urinary symptoms.
  • Medications.
  • Recent procedures or infections.
  • Physical examination and imaging findings.

Noncancerous causes of elevated PSA

A higher-than-expected PSA level may result from:

  • Benign prostatic hyperplasia, or noncancerous prostate enlargement.
  • Prostatitis or other inflammation.
  • Urinary infection.
  • Recent urinary or prostate procedures.
  • Temporary changes related to ejaculation or certain activities, depending on clinical advice.
  • Prostate cancer.

Some medications lower PSA levels and affect interpretation. Men should provide a complete list of prescription drugs, over-the-counter products, and supplements.

What happens after a PSA test?

An abnormal PSA result does not automatically indicate cancer or require an immediate biopsy. A clinician may:

  1. Review the result and compare it with previous measurements.
  2. Ask about symptoms, infection, medications, and recent procedures.
  3. Repeat the PSA test after an appropriate interval.
  4. Perform a clinical examination when indicated.
  5. Use a risk calculator or additional biomarker test.
  6. Recommend imaging, including multiparametric MRI, when appropriate.
  7. Recommend biopsy if the overall risk justifies it.

A biopsy obtains prostate tissue for microscopic examination. It can cause bleeding, pain, infection, and temporary urinary problems. The decision should consider the likelihood of clinically important cancer and the possible harms of the procedure. Source 3

Why Use a Two-Year Testing Interval?

For selected men, testing every two years may provide continued monitoring with fewer blood tests, appointments, borderline results, and unnecessary follow-up procedures than annual testing. These are potential benefits, not guarantees.

Screening attempts to detect clinically important cancer before symptoms develop. Earlier detection may provide more treatment options and improve outcomes for some aggressive cancers. However, screening can also cause overdiagnosis: finding a cancer that would never have caused symptoms or shortened a person’s life.

Overdiagnosis can lead to repeat PSA tests, imaging, biopsy, active surveillance, surgery, radiation, anxiety, and long-term urinary, bowel, or sexual side effects.

Why some men may need annual testing

Annual testing may be considered when a man has:

  • A PSA level of 2.5 ng/mL or higher.
  • A rising PSA requiring closer evaluation.
  • A previous abnormal biopsy or suspicious MRI.
  • A strong family history.
  • A known inherited cancer-risk variant.
  • A higher-risk racial or ethnic background recognized in applicable guidance.
  • Clinical findings that increase concern.

A normal result does not permanently establish a two-year schedule. The plan should be reviewed after each test and whenever health or risk factors change.

Benefits and Limitations of Screening

PSA screening may detect some cancers before symptoms develop, identify certain aggressive cancers earlier, provide information about risk over time, and support structured monitoring.

Potential limitations include:

  • False-positive or false-negative results.
  • Anxiety while awaiting repeat testing or biopsy.
  • Unnecessary biopsies.
  • Detection and treatment of slow-growing cancers.
  • Urinary, bowel, sexual, or emotional effects from treatment.
  • Confusion caused by PSA changes unrelated to cancer.

The United States Preventive Services Task Force describes PSA screening as an individual decision for men aged 55 to 69 and recommends against routine PSA-based screening for men aged 70 or older because potential harms generally outweigh benefits in that age group. Source 4

Different organizations use different approaches. Men should ask which guideline their healthcare professional follows and how it applies to their circumstances.

PSA testing may detect cancer earlier, but it does not prevent prostate cancer. Screening is generally intended for people without symptoms. Men with symptoms should seek medical assessment rather than wait for routine testing.

Preparing for a Screening Discussion

Before an appointment, prepare information about:

  • Age and general health.
  • Previous PSA results.
  • Prostate enlargement, prostatitis, or urinary infection.
  • Current urinary symptoms.
  • Medications and supplements.
  • Cancer diagnoses among close relatives.
  • Genetic testing results.
  • Previous prostate biopsy or imaging.

Ask the healthcare professional:

  • Am I average risk or higher risk?
  • Should I begin or continue PSA screening?
  • Is testing every two years appropriate for my age and PSA level?
  • Could medication or a recent infection affect the result?
  • When should I repeat the test if the result is normal?
  • What result would lead to additional evaluation?
  • Would biomarkers or MRI be useful?
  • What are the benefits and risks of biopsy?
  • How do my health and life expectancy affect screening?

Understanding possible follow-up helps prevent an abnormal result from being mistaken for an immediate cancer diagnosis.

Understanding PSA Results

A normal result

A normal PSA level lowers concern but does not eliminate the possibility of prostate cancer. Some cancers produce little PSA, and PSA thresholds do not work perfectly for everyone. Continue screening according to the agreed plan, and report new or persistent symptoms before the next scheduled test.

A higher-than-expected result

One elevated result does not establish a diagnosis. The clinician may repeat the PSA or investigate infection, inflammation, prostate enlargement, medications, and recent procedures.

Men should interpret PSA results using the laboratory’s reference information and their medical history. The same level can have different significance in different clinical situations.

A rising PSA level

A PSA trend can provide useful information, but PSA velocity should not be considered alone. Clinicians may also evaluate age, prostate volume, previous values, family history, genetic risk, examination findings, MRI, and other biomarkers.

Symptoms Requiring Medical Evaluation

Possible urinary or prostate-related symptoms include:

  • Difficulty starting urination.
  • Weak or interrupted urine flow.
  • Frequent or urgent urination.
  • Blood in the urine or semen.
  • Painful ejaculation.
  • Persistent pain in the back, hips, pelvis, or upper thighs.

These symptoms do not automatically indicate prostate cancer. Benign prostate enlargement, infection, kidney stones, and other conditions can cause similar problems.

A man with persistent or concerning symptoms should contact a healthcare professional instead of waiting for the next routine PSA test. Inability to urinate, significant bleeding, fever, or severe pain requires prompt medical attention.

Conclusion

The American Cancer Society supports informed decision-making about prostate cancer screening rather than one schedule for every man. For men who choose PSA testing, those with lower PSA levels may be able to repeat testing every two years, while men with higher PSA levels or greater risk may need closer monitoring.

PSA estimates risk; it does not diagnose cancer. An abnormal result usually requires further evaluation, not immediate treatment. Family history, inherited risk, race, previous PSA results, age, and overall health can change the screening plan.

Average-risk men should review their personal and family history, confirm whether screening is appropriate, and discuss the testing interval with a healthcare professional. Men with urinary or other concerning symptoms should seek medical evaluation rather than wait for routine screening.

Frequently Asked Questions

Is a PSA test the same as a prostate cancer diagnosis?

No. PSA testing measures a protein associated with prostate tissue. A higher PSA can result from cancer, prostate enlargement, inflammation, infection, or other factors. Diagnosis usually requires additional evaluation and, when indicated, a biopsy.

How often should an average-risk man have a PSA test?

The ACS approach allows a two-year interval for some men with lower PSA levels who choose screening. Men with PSA levels of 2.5 ng/mL or higher may need annual testing. Age, health, family history, previous results, and clinical assessment also affect the schedule.

Does a normal PSA make prostate cancer impossible?

No. A normal result lowers concern but cannot rule out every prostate cancer. Continue monitoring according to the agreed plan and report new or persistent symptoms.

What can cause a high PSA besides cancer?

Benign prostate enlargement, inflammation, infection, recent urinary or prostate procedures, and some temporary factors can raise PSA. A clinician may repeat the test or investigate other causes before recommending a biopsy.

Who may need earlier or more frequent screening?

Men with a strong family history, relevant inherited risk, Black or African American identity, or previous abnormal findings may need earlier or more frequent screening discussions. The plan should be individualized.

Should men with urinary symptoms wait for their next PSA test?

No. Urinary symptoms should be evaluated rather than managed only through routine screening. Symptoms can have several causes, including conditions unrelated to prostate cancer.

4 views